{"Clinical Trial ID": "NCT00728949", "Intervention": ["INTERVENTION 1:", "IMC-A12 (Cixutumumab) + Estrogen treatment", "Participants will receive IMC-A12 10 mg/kg intravenously over one hour every two weeks, as well as the same dose and schedule of the last antistrogen therapy to which their disease has become refractory.", "INTERVENTION 2:", "IMC-A12 (Cixutumumab)", "Participants will only receive BMI-A12 (10 mg/kg in 1 hour every 2 weeks)."], "Eligibility": ["Incorporation criteria:", "The patient is suffering from histologically or cytologically confirmed invasive breast cancer, which, at the time of entry into the study, is either a stage III disease (locally advanced) not susceptible to curative treatment or stage IV disease. Histological confirmation of a recurrent/metastatic disease is not required if clinical evidence of recurrence of stage IV disease is available.", "The tumours are positive for estrogen receptors (ER), progesterone receptors (PgR), or both (i.e. 10% or more of infiltrated cancer cells exhibit nuclear staining for ER and/or PgR; positive biochemical test results are also acceptable).", "The patient received prior antiestrogen treatment:", "With at least one antistrogen agent (with or without ovarian suppression) administered for 3 months in an adjuvant or metastatic medium; and", "A progression of the disease was observed during or within 12 months of the last endocrine dose.", "The patient is postmenopausal and/or meets at least one of the following criteria:", "18 years old with an intact uterus and amenorrhoea for 12 months, with estradiol and/or follicle-stimulating hormone (FSH) values in the postmenopausal interval", "History of bilateral ophorectomy", "History of bilateral salpingo-oophorectomy", "History of radiation castration and amenorrhea for 3 months", "The patient has fasting blood glucose < 120 mg/dL or less than ULN", "- Exclusion criteria:", "The patient received more than two previous chemotherapy regimens in the metastatic setting (or locally advanced and inoperative) and in the adjuvant setting", "Patients with a history of diabetes mellitus are allowed to participate in the study, provided that their blood sugar levels are within a normal range (fast blood glucose levels at baseline < 120 mg/dL or below the NSA) and that they are on a stable diet and/or therapy for this condition.", "The patient is known to be positive for human immunodeficiency virus infection"], "Results": ["Performance measures:", "- Progression-free survival (PFS)", "The progression is defined using the criteria for evaluation of response in solid tumour criteria (RECIST v1.0), such as a 20% increase in the sum of the longest diameter of the target lesions, or a measurable increase in a non-target injury, or the appearance of new lesions, an unequivocal progression of non-target lesions. Participants without progression or death documentation will be censored at the date of the last tumour evaluation. The PFS will be estimated using the Kaplan-Meier method.", "Time limit: Randomization up to 35.1 months", "Results 1:", "Title of the arm/group: IMC-A12 (Cixutumumab) + Estrogen therapy", "Description of the arm/group: Participants will receive IMC-A12 10 mg/kg intravenously over one hour every two weeks, as well as the same dose and schedule of the last antistrogen therapy to which their disease has become refractory.", "Total number of participants analysed: 62", "Median (90% confidence interval)", "Unit of measure: month 2.0 (1.9 to 3.4)", "Results 2:", "Title of arm/group: IMC-A12 (Cixutumumab)", "Description of the arm/group: Participants will only receive BMI-A12 (10 mg/kg in one hour every 2 weeks).", "Total number of participants analysed: 31", "Median (90% confidence interval)", "Unit of measure: month 3.1 (1.9 to 4.2)"], "Adverse Events": ["Undesirable Events 1:", "Total: 16/56 (28.57 per cent)", "Pancytopenia 0/56 (0.00 %)", "Pericarditis 0/56 (0.00 %)", "Abdominal pain 1/56 (1.79%)", "Anal fissure 1/56 (1.79 %)", "Ascites 1/56 (1.79 %)", "Constipation 0/56 (0.00 %)", "Diarrhoea 1/56 (1.79%)", "Nausea 0/56 (0.00 %)", "Esophagus pain 0/56 (0.00 %)", "Vomiting 0/56 (0.00 %)", "\u2022 Disease progression 2/56 (3.57 per cent)", "Infusion-related reaction 1/56 (1.79%)", "- Pain 0/56 (0.00 %)", "Adverse Events 2:", "Total: 11/37 (29.73%)", "Pancytopenia 1/37 (2.70%)", "Pericarditis 1/37 (2.70%)", "Abdominal pain 2/37 (5.41%)", "- Anal fissure 0/37 (0.00 %)", "Ascites 0/37 (0.00 %)", "Constipation 1/37 (2.70%)", "Diarrhoea 1/37 (2.70%)", "Nausea 2/37 (5.41%)", "Esophagus pain 1/37 (2.70%)", "- Vomiting 2/37 (5.41%)", "Rate of disease progression 2/37 (5.41%)", "Infusion-related reaction 0/37 (0.00 %)", "Pain 1/37 (2.70%)"]}